(6S)-2,8,14-Triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),11,13-triene

Catalog No. :
ACIAJB324
CAS No. :
2059912-18-2
Molecular Formula :
C11H15N3
Molecular Weight :
189.26

IUPAC Name:(S)-6,7,7a,8,9,10-hexahydro-5H-pyrido[3,2-f]pyrrolo[1,2-a][1,4]diazepine

(6S)-2,8,14-Triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),11,13-triene structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$237.00Login to see priceInquiryInquiry
100mg95%$341.00Login to see priceInquiryInquiry
250mg95%$478.00Login to see priceInquiryInquiry
1g95%$950.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(6S)-2,8,14-Triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),11,13-triene
IUPAC Name(S)-6,7,7a,8,9,10-hexahydro-5H-pyrido[3,2-f]pyrrolo[1,2-a][1,4]diazepine
MDL No.MFCD30536011
Molecular FormulaC11H15N3
Molecular Weight189.26
SMILES[H][C@@]12CCCN1C3=C(C=CC=N3)CNC2
InChI KeyXHLZWHZPUMPINL-JTQLQIEISA-N
Synonym(6S)-2,8,14-triazatricyclo[8.4.0.0,2,6]tetradeca-1(14),10,12-triene;(6S)-2,8,14-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),11,13-triene;5H-Pyrido[3,2-f]pyrrolo[1,2-a][1,4]diazepine, 6,7,7a,8,9,10-hexahydro-, (7aS)-
CAS No.2059912-18-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACIAJB324 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIAJB324 route product structure diagram
    ACIAJB3242059912-18-2
Inquiry

2. ACIAJB324 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIAJB324 route product structure diagram
    ACIAJB3242059912-18-2
Inquiry

Comments (0)